Analyst Ratings For Stryker

Analysts' ratings for Stryker SYK over the last quarter vary from bullish to bearish, as provided by 9 analysts.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $380.44, a high estimate of $406.00, and a low estimate of $360.00. This current average reflects an increase of 5.5% from the previous average price target of $360.62.

Diving into Analyst Ratings: An In-Depth Exploration

The standing of Stryker among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Stryker. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Stryker compared to the broader market.
• Price Targets: Gaining insights, analysts provide estimates for the future value of Stryker's stock. This comparison reveals trends in analysts' expectations over time.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Stryker's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Stryker analyst ratings.

Unveiling the Story Behind Stryker

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.

Understanding the Numbers: Stryker's Finances

Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.

Revenue Growth: Over the 3 months period, Stryker showcased positive performance, achieving a revenue growth rate of 11.78% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Stryker's net margin excels beyond industry benchmarks, reaching 19.66%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Stryker's ROE stands out, surpassing industry averages. With an impressive ROE of 6.26%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): Stryker's ROA stands out, surpassing industry averages. With an impressive ROA of 2.93%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: Stryker's debt-to-equity ratio is below the industry average. With a ratio of 0.7, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

How Are Analyst Ratings Determined?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

This article was generated by Benzinga's automated content engine and reviewed by an editor.